# Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma

> **NCT03477539** · PHASE2 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 49 (actual)

## Conditions studied

- Plasma Cell Myeloma

## Interventions

- **PROCEDURE:** Autologous Hematopoietic Stem Cell Transplantation
- **BIOLOGICAL:** Daratumumab
- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT03477539
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-09
- **Primary completion:** 2022-05-11
- **Final completion:** 2025-03-24
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03477539

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03477539, "Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT03477539. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*